External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

Value Investors Club (.com) is an exclusive online investment club where top investors share their best ideas. Content available at the above link/PDF preview is an external article authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

Key points (machine generated)<ul><li>Opus Genetics is a clinical-stage gene therapy company founded in 2021, focusing on inherited retinal diseases.</li><li>The lead program, OPGx-LCA5, is in a Phase I/II study showing vision improvements, with preliminary pediatric data expected in Q3 2025.</li><li>Opus is also developing OPGx-BEST1 for retinal diseases, with a Phase I/II trial starting in late 2025, and has a speculative risk/reward profile.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Opus Genetics is a clinical-stage gene therapy company founded in 2021, focusing on inherited retinal diseases.The lead program, OPGx-LCA5, is in a Phase I/II study showing vision improvements, with preliminary pediatric data expected in Q3 2025.Opus is also developing OPGx-BEST1 for retinal diseases, with a Phase I/II trial starting in late 2025, and has a speculative risk/reward profile.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Opus Genetics Inc (IRD) - Thursday, Jul 3, 2025